1/ Four years ago, cofounders Jack O'Meara and Quin Wills met on the EF program in London and built Ochre Bio from scratch. Now, they’ve signed an up to $1bn partnership with pharma group Boehringer Ingelheim to develop novel RNA medicines for under-treated chronic liver diseases.

Congratulations are in order for our newly promoted team-members! 👏 Thank you all for your continued hard work! #TeamOchre

Last week was an exciting one, as we celebrated our partnership with Boehringer Ingelheim – thank you all for your enthusiasm & excitement! 🙌 It was incredible to see the partnership covered in all corners of the media! endpts.com/boehringer-ing… #TeamOchre

Last week, CEO Jack O'Meara spoke to BiotechTV about the major challenge of liver disease, and our human-first approach to tackling it. Watch the full interview ➡️ biotechtv.com/post/ochre-bio…

We’re pleased to welcome Joanne Soong to our NY team as our new Lab Manager! 🧪Joanne holds a PhD from the University of Rochester Medical Center and has many years experience in lab management at top institutions. Welcome to #TeamOchre Joanne!

Our Head of Corporate Development Jack Castle will be speaking on a panel for the Controlled Release Society: Joining the Dots: Connecting Science and Business 🧑‍💻Online 🗓️5 June 16:00 CET The webinar will examine the gap between science innovation & business strategy. form.jotform.com/241432352335347

🇮🇹 This week, our Vice President of Translational Development David Coughlan, is at the EASLnews #EASLCongress2024. David will be attending today and tomorrow, so if you want to arrange a meeting, get in touch! View the full programme: easlcongress.eu

MASH affects 1.5-6.45% of the global population. Great to see our name in this Nature Biotechnology article, highlighting how some innovative biotechs are helping uncover the molecular mechanisms underpinning this underserved disease ➡️ nature.com/articles/s4158…

Yesterday, Switchboard visited our Oxford Team to discuss how small, actionable changes can create significant support in the workplace & beyond. #PrideMonth is the perfect time to celebrate our LGBTQIA+ colleagues and discuss how we can be better allies. 🏳️‍🌈 #TeamOchre

🎙️Quin Wills, our CSO and Co-Founder joined Jon Chee on The Biotech Startups Podcast talk about genetics, bioinformatics, big data, and much more! 🎧 Catch all 4 episodes now: open.spotify.com/episode/1uDjWx…

💬Last year, Quin Wills, our Co-Founder & CSO, took to the TEDx stage to talk about developing RNA therapies for chronic liver disease. Quin discusses how we are using #machinelearning & human-first approaches to develop novel therapies. 🎥: youtu.be/bE1W4080zgU?fe… #TeamOchre

🏆 Congratulations to our Quarterly Values Champions! The winners embody our core #TeamOchre principles: innovation, resilience and teamwork ⬇️ 🌟Fleur Palmer-Paquis - Clarke's Law 🌟Esther Arnaiz - Murphy's Law 🌟Anthony Beucher - Wheaton's Law

Welcoming 2 new members to our NY team... Say hello to 🧬Nicola, our new Scientist, and 🩺Ahmad, our new Clinical Research Scientist! 👋 #TeamOchre

🎉 Celebrating Wheaton's Day at our Oxford site! This year, #TeamOchre took part in a back-2-back origami workshop, where pairs created origami models together. The exercise emphasised effective communication & reminded us to think about others before speaking⬇️

🌟 We’re honoured to be featured by Sifted and EUStartupNews as a top biotech company in 2024! This caps off a year of big wins, including Boehringer Ingelheim & GSK partnerships for our late-stage #LiverDisease research. 1️⃣sifted.eu/scout/drug-dis… 2️⃣eu-startups.com/2024/07/leadin…

Research from Sanford Burnham Prebys & UC San Diego shows that macrophages support liver repair in patients with advanced liver fibrosis. Understanding signatures of complex liver disease processes is vital in developing therapies for late-stage liver diseases. news-medical.net/news/20240822/…

🎉 Some more congratulations are in order for our new batch of promoted team members! Thank you all for your continued hard work 👏 #TeamOchre